Kashiv Biosciences Strengthens Leadership Team
Kashiv BioSciences, a prominent player in the biopharmaceutical sector, has announced significant additions to its leadership team by appointing Mandar Borkar as the Global Chief Financial Officer and Ross Oehler as the Global Chief Legal Officer.
New Appointments to Fuel Growth
Chirag and Chintu Patel, the visionary co-founders of Kashiv BioSciences, expressed their enthusiasm, stating, “We are pleased to welcome Mandar Borkar and Ross Oehler to the management team. With two approved products on the market and a rapidly advancing pipeline, we are confident that their expertise will play a pivotal role in advancing Kashiv to new heights.”
Experience and Expertise of Mandar Borkar
Mandar Borkar is no stranger to the pharmaceutical industry. With over 25 years of rich experience, he has expertly managed intricate financial structures and led transformative finance initiatives. His impressive career boasts significant roles at reputable firms such as Mahindra & Mahindra, Parke Davis, Lupin, and Watson Pharma. In his previous role as CFO for Indoco Remedies, Borkar successfully optimized operational efficiency while positioning the company for sustainable financial growth.
Before joining Kashiv, he was integral to Abbott's Financial Controlling Function, where he ensured transparency in financial reporting and compliance and drove innovative enhancements in finance operations. Borkar's credentials include membership in both the Institute of Chartered Accountants of India and the Institute of Cost and Management Accountants of India, alongside his Bachelor's degree in Commerce from Mumbai University.
Ross Oehler's Role in Legal Affairs
Joining Kashiv, Ross Oehler brings a wealth of knowledge and expertise accumulated over more than 30 years in the biopharmaceutical industry. His previous tenures at Sanofi-Aventis, Cephalon Inc., and Johnson Matthey, Inc., equipped him with insights to handle complex legal matters effectively. Oehler oversees global legal and intellectual property groups at Kashiv, supporting critical functions such as IP, litigation, corporate governance, regulatory policy, and compliance.
His extensive experience includes involvement in multiple intellectual property and commercial disputes across US Federal Courts, the International Trade Commission, and European Patent Offices. Oehler is an active member of the Association of Corporate Counsel and the Association of Corporate Patent Counsel. He holds a Juris Doctor from New York Law School and a Bachelor's degree in Biology from Gettysburg College, demonstrating his robust foundation in both law and science.
About Kashiv BioSciences
Kashiv BioSciences is a vertically integrated biopharmaceutical company, boasting a diverse portfolio of commercial and advanced clinical-stage assets. Known for its strong infrastructure and skilled teams, Kashiv operates efficiently within the United States and collaborates with its subsidiaries in India. The company prides itself on its comprehensive capabilities in global R&D, clinical, manufacturing, regulatory, and intellectual property sectors, believing that its people, partners, and shared purpose are essential in enhancing patient care and expanding access to vital medicines.
Frequently Asked Questions
What are the recent changes in Kashiv Biosciences' leadership?
Kashiv Biosciences appointed Mandar Borkar as CFO and Ross Oehler as CLO, enhancing their leadership capabilities.
What is the experience of Mandar Borkar?
Mandar Borkar brings over 25 years of financial expertise in the pharmaceutical sector, having held various strategic roles in reputable companies.
What will Ross Oehler's role be at Kashiv?
Ross Oehler will oversee global legal affairs, including IP, litigation, regulatory policy, and compliance.
What are the key areas of focus for Kashiv Biosciences?
Kashiv focuses on R&D, clinical capabilities, manufacturing, and regulatory processes to enhance patient care.
How does Kashiv BioSciences operate globally?
Kashiv operates with a strong infrastructure and skilled teams in the U.S. and its subsidiaries in India, providing comprehensive biopharmaceutical solutions.
